Lyudmila A. Bazhenova, MD, medical oncologist, professor, medicine, the University of California San Diego (UCSD) Moores Cancer Center, discusses factors to consider when navigating the use of...
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival (DFS) in early-risk, high-risk, HER2-negative breast cancer and germline patients. BRCA Mutations, according to...
Recent Comments